Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Ajaz Hussain Leaving FDA for Sandoz

Ajaz Hussain Leaving FDA for Sandoz

Ajaz Hussain, the high-profile deputy director of the US Food and Drug Administration’s Office of Pharmaceutical Science (OPS), is leaving the agency on Oct. 28 to join Sandoz (Holzkirchen, Germany) as vice-president and global head for biopharmaceutical development. 

In a Tuesday-evening announcement, OPS Director Helen N. Winkle called Hussain “the tireless champion of pharmaceutical product quality and a leader of numerous initiatives in FDA such as the 'Pharmaceutical CGMPs for the 21st Century-A Risk-Based Approach’” and “architect of CDER's Process Analytical Technologies efforts.”

Earlier in his FDA career, Hussain played key roles in the Center for Drug Evaluation and Research’s (CDER) Scale-up and Postapproval Changes (SUPAC) and Biopharmaceutics Classification System (BCS) initiatives.

Sandoz, the generics subsidiary of Novartis, sued FDA on Sept. 13, trying to force FDA to rule on the company’s follow-on biologic application for “Omnitrope,” a recombinant human growth hormone. For more information.

–Douglas McCormick

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content